Tandem Diabetes Care, Inc. (TNDM) posted a third-quarter 2024 loss of 36 cents per share compared with the year-ago quarter’s reported loss of 38 cents. The figure beat the Zacks Consensus Estimate of a loss of 43 cents per share.On a GAAP basis, the loss was 35 cents per share compared with the year-ago loss of 51 cents.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the earnings announcement, TNDM stock fell 2% in aftermarket trading yesterday. TNDM’s Q3 RevenuesGAAP reven ...

Core Insights - Tandem Diabetes Care, Inc. reported a revenue of $243.97 million for the quarter ended September 2024, reflecting a year-over-year increase of 31.4% [1] - The company's EPS was -$0.36, an improvement from -$0.38 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $223.33 million by 9.24%, and the EPS also surpassed the consensus estimate of -$0.43 by 16.28% [1] Performance Metrics - Total worldwide pump shipments reached 32,000, exceeding the average estimate of 29,722 [3] - Pump shipments outside the United States were 11,000, compared to the estimated 8,738 [3] - In the United States, pump shipments totaled 21,000, slightly above the average estimate of 20,985 [3] - U.S. pump sales amounted to $86.72 million, surpassing the average estimate of $84.60 million, marking a 30.7% increase year-over-year [3] - Sales of supplies and other in the U.S. were $83.89 million, exceeding the estimate of $78.68 million, representing a 16.4% year-over-year increase [3] - Geographic sales outside the U.S. reached $72.32 million, compared to the average estimate of $59.84 million, reflecting a 30.5% year-over-year increase [3] - U.S. geographic sales totaled $171.65 million, exceeding the estimate of $163.28 million, with a year-over-year increase of 31.8% [3] - Sales of supplies and other outside the U.S. were $44.24 million, surpassing the estimate of $37.44 million, indicating a 31.2% year-over-year increase [3] - Pump sales outside the U.S. reached $28.08 million, exceeding the estimate of $22.34 million, with a year-over-year increase of 29.6% [3] - Revenue from supplies and other was $128.13 million, compared to the average estimate of $115.91 million [3] - Pump revenue was $114.80 million, exceeding the average estimate of $107.07 million [3] Stock Performance - Tandem Diabetes Care's shares have declined by 17% over the past month, while the Zacks S&P 500 composite has increased by 0.7% [4] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [4]

Company Performance - Tandem Diabetes Care, Inc. reported a quarterly loss of $0.36 per share, better than the Zacks Consensus Estimate of a loss of $0.43, and compared to a loss of $0.38 per share a year ago, representing an earnings surprise of 16.28% [1] - The company posted revenues of $243.97 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 9.24%, and compared to year-ago revenues of $185.62 million [2] - Over the last four quarters, Tandem Diabetes Care has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Stock Outlook - The stock has added about 11.9% since the beginning of the year, underperforming the S&P 500's gain of 21.2% [3] - The current consensus EPS estimate for the coming quarter is -$0.21 on revenues of $252.34 million, and for the current fiscal year, it is -$1.76 on revenues of $889.57 million [7] - The estimate revisions trend for Tandem Diabetes Care is favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Instruments industry, to which Tandem Diabetes Care belongs, is currently in the top 36% of over 250 Zacks industries, suggesting a positive outlook for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Third Quarter 2024 Financial Report [Third Quarter 2024 Highlights](index=1&type=section&id=Third%20Quarter%202024%20Highlights) Tandem Diabetes Care reported record Q3 2024 sales, achieving 31% growth, positive Adjusted EBITDA, and expanding Control-IQ indication | Metric | Q3 2024 | Change vs Q3 2023 | | :--- | :--- | :--- | | Worldwide GAAP Sales | $244.0 million | +31% | | Worldwide Non-GAAP Sales | $242.9 million | +25% | - Worldwide pump shipments grew by more than **25%** compared to the third quarter of 2023[3](index=3&type=chunk) - The company achieved year-over-year growth in new pump starts in the United States, including from patients previously on multiple daily injections[3](index=3&type=chunk) - Demonstrated **positive Adjusted EBITDA** and a return to **positive free cash flow**[3](index=3&type=chunk) - Completed a clinical study to support a regulatory filing for expanding the Control-IQ indication to people with type 2 diabetes[3](index=3&type=chunk) [Third Quarter 2024 Financial Results](index=1&type=section&id=Third%20Quarter%202024%20Financial%20Results) Tandem's Q3 2024 financial results show strong sales growth, improved gross margin, and narrowed GAAP operating and net losses Q3 2024 vs Q3 2023 Sales Performance ($ in millions) | Region | Q3 2024 GAAP Sales | Q3 2023 GAAP Sales | Q3 2024 Non-GAAP Sales | Q3 2023 Non-GAAP Sales | | :--- | :--- | :--- | :--- | :--- | | United States | $171.7 | $130.2 | $170.6 | $138.5 | | Outside U.S. | $72.3 | $55.4 | $72.3 | $55.4 | | **Total Worldwide** | **$244.0** | **$185.6** | **$242.9** | **$193.9** | - Total pump shipments for Q3 2024 were approximately **32,000 units**, with ~**21,000** in the U.S. and nearly **11,000** outside the U.S. (Note: U.S. shipments do not include pumps fulfilled under Tandem Choice)[7](index=7&type=chunk) Q3 2024 vs Q3 2023 Profitability Metrics ($ in millions) | Metric | Q3 2024 GAAP | Q3 2023 GAAP | Q3 2024 Non-GAAP | Q3 2023 Non-GAAP | | :--- | :--- | :--- | :--- | :--- | | Gross Profit | $124.7 | $89.8 | $124.3 | $98.0 | | Gross Margin | 51% | 48% | 51% | 51% | | Operating Loss | $(26.1) | $(31.5) | $(26.5) | $(23.3) | | Net Loss | $(23.3) | $(33.0) | $(23.6) | $(24.7) | | Adjusted EBITDA | $4.0 | $1.5 | - | - | [2024 Financial Guidance](index=3&type=section&id=2024%20Financial%20Guidance) Tandem increased its full-year 2024 non-GAAP sales guidance to $903-$910 million, while reaffirming gross margin and Adjusted EBITDA targets Updated Full-Year 2024 Non-GAAP Guidance | Metric | Guidance | | :--- | :--- | | Non-GAAP Sales | $903 million to $910 million | | - U.S. Sales | $645 million to $650 million | | - OUS Sales | $258 million to $260 million | | Non-GAAP Gross Margin | Approx. 51% | | Adjusted EBITDA Margin | Breakeven as % of sales | - Projected non-cash charges for 2024 are estimated at approximately **$120 million**, consisting of **$100 million** in stock-based compensation and **$20 million** in depreciation and amortization[12](index=12&type=chunk) [Explanation of Non-GAAP Financial Measures](index=4&type=section&id=Explanation%20of%20Non-GAAP%20Financial%20Measures) Non-GAAP measures are presented to clarify core operating performance by excluding the accounting complexities of the Tandem Choice Program - Non-GAAP measures are used to exclude items unrelated to core operating results, primarily the accounting for the Tandem Choice program[13](index=13&type=chunk) - The Tandem Choice program allowed eligible t:slim X2 customers to upgrade to a Tandem Mobi pump for a fee. The program's complexity led to sales deferrals[15](index=15&type=chunk) - The balance of the Tandem Choice deferral was **$30.1 million** as of September 30, 2024, with any remaining deferrals expected to be recognized in Q4 2024 upon the program's expiration on December 31, 2024[16](index=16&type=chunk) [Consolidated Financial Statements](index=6&type=section&id=Consolidated%20Financial%20Statements) Consolidated financial statements detail Tandem's financial position, strong revenue growth, narrowing net loss, and GAAP to non-GAAP adjustments [Condensed Consolidated Balance Sheets (Table A)](index=6&type=section&id=Table%20A%20Condensed%20Consolidated%20Balance%20Sheets) Tandem's balance sheet as of September 30, 2024, shows stable assets at $957.7 million and increased total liabilities to $720.0 million Balance Sheet Highlights (in thousands) | Account | Sep 30, 2024 (Unaudited) | Dec 31, 2023 | | :--- | :--- | :--- | | Cash, cash equivalents and short-term investments | $473,305 | $467,912 | | Total current assets | $752,826 | $747,989 | | Total assets | $957,730 | $952,658 | | Total current liabilities | $259,276 | $195,258 | | Total liabilities | $720,020 | $639,026 | | Total stockholders' equity | $237,710 | $313,632 | [Condensed Consolidated Statements of Operations (Table B)](index=7&type=section&id=Table%20B%20Condensed%20Consolidated%20Statements%20of%20Operations) Q3 2024 GAAP net loss significantly narrowed to $23.3 million, or ($0.35) per share, reflecting improved operational performance Statement of Operations Summary (in thousands, except per share data) | Metric | Three Months Ended Sep 30, 2024 | Three Months Ended Sep 30, 2023 | Nine Months Ended Sep 30, 2024 | Nine Months Ended Sep 30, 2023 | | :--- | :--- | :--- | :--- | :--- | | Sales | $243,971 | $185,622 | $657,555 | $550,922 | | Gross Profit | $124,653 | $89,753 | $332,119 | $274,395 | | Operating Loss | $(26,093) | $(31,545) | $(98,545) | $(198,170) | | Net Loss | $(23,251) | $(32,961) | $(96,780) | $(192,609) | | Net Loss Per Share | $(0.35) | $(0.51) | $(1.48) | $(2.97) | [Sales by Geography (Table C)](index=8&type=section&id=Table%20C%20Sales%20by%20Geography) Q3 2024 total GAAP sales grew 31% year-over-year, with strong pump and supplies growth in both U.S. and international markets Q3 2024 vs Q3 2023 GAAP Sales Growth by Geography & Product ($ thousands) | Category | Q3 2024 Sales | % Change YoY | | :--- | :--- | :--- | | **United States** | **$171,650** | **+32%** | | - Pump | $86,722 | +31% | | - Supplies & Other | $83,889 | +16% | | **Outside the U.S.** | **$72,321** | **+31%** | | - Pump | $28,077 | +30% | | - Supplies & Other | $44,244 | +31% | | **Total Worldwide** | **$243,971** | **+31%** | [Reconciliation of GAAP versus Non-GAAP Financial Results (Table D)](index=9&type=section&id=Table%20D%20Reconciliation%20of%20GAAP%20versus%20Non-GAAP%20Financial%20Results) This section reconciles GAAP to non-GAAP results, highlighting adjustments for the Tandem Choice program and positive Adjusted EBITDA Q3 2024 GAAP to Non-GAAP Reconciliation ($ in thousands) | Metric | GAAP | Adjustment for Tandem Choice | Non-GAAP | | :--- | :--- | :--- | :--- | | Sales | $243,971 | $(1,039) | $242,932 | | Gross Profit | $124,653 | $(374) | $124,279 | | Operating Loss | $(26,093) | $(374) | $(26,467) | | Net Loss | $(23,251) | $(374) | $(23,625) | Adjusted EBITDA Calculation - Q3 2024 vs Q3 2023 ($ in thousands) | Metric | Q3 2024 | Q3 2023 | | :--- | :--- | :--- | | GAAP Net Loss | $(23,251) | $(32,961) | | (+) Adjustments* | $27,276 | $34,416 | | **Adjusted EBITDA** | **$4,025** | **$1,455** |

Core Viewpoint - Tandem Diabetes Care, Inc. (TNDM) has experienced a significant decline of 21.7% over the past four weeks, but it is now positioned for a potential trend reversal as it enters oversold territory, with analysts predicting better earnings than previously expected [1]. Group 1: Stock Performance and Indicators - TNDM's Relative Strength Index (RSI) reading is at 29.87, indicating that the heavy selling pressure may be exhausting, suggesting a possible bounce back towards previous supply and demand equilibrium [3]. - The stock is considered oversold when its RSI falls below 30, which is a common threshold for identifying potential price reversals [2]. Group 2: Earnings Estimates and Analyst Consensus - There is strong consensus among sell-side analysts that earnings estimates for TNDM have increased by 0.1% over the last 30 days, indicating a positive outlook for the company's financial performance [4]. - TNDM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [4].

Tandem Diabetes Care (TNDM) has achieved a significant milestone by gaining approval for the use of its t:slim X2 insulin pump with Eli Lilly's ultra-rapid acting insulin, Lyumjev, in the European Union (EU). The compatibility with Lyumjev offers new possibilities in the insulin delivery landscape, enhancing the efficacy of Tandem's automated insulin delivery (AID) systems. This latest development strengthens Tandem's position in the diabetes technology market and enhances its offerings for individuals with ...

Tandem Diabetes (TNDM) is gaining from continued product innovations. Yet, ongoing macroeconomic challenges and tough competition pose challenges. The stock carries a Zacks Rank #3 (Hold) currently. Factors Driving TNDM Stock Tandem Diabetes seeks to grow its business through the acquisition of products or technologies or investments in businesses. Last year, it acquired Swiss-based AMF Medical SA — the developer of the Sigi Patch Pump. The company's speed-to-market with Continuous Glucose Monitoring (CGM) ...

Tandem Diabetes Care, Inc.'s (TNDM) flagship t:slim X2 insulin pump with Control-IQ automated insulin delivery (AID) technology is now certified for use with Eli Lilly and Company's (LLY) Lyumjev (insulin lispro-aabc injection) ultra-rapid acting insulin in the European Union (EU). The development follows a clinical study that reported high satisfaction and quality of life benefits by pairing Lyumjev with Control-IQ technology. Ultra-rapid acting insulin is a popular choice for people living with diabetes b ...

At a stroke, it's got a product authorized for a specific use in 27 countries. Tandem Diabetes Care (TNDM 4.25%) had some encouraging news to report on the regulatory front Thursday, and after it hit the headlines investors piled into the stock. At the end of the day the highly specialized healthcare company's share price had risen in excess of 4%, good enough to top the 1.7% rise of the benchmark S&P 500 index. Crucial approval granted Tandem announced Thursday morning that it had won an important approval ...

Tandem Diabetes Care, Inc.'s (TNDM) growth is backed by its impressive range of new products. The flourishing diabetes market provides a favorable opportunity for the company's growth. However, concerns loom over Tandem Diabetes' substantial reliance on insulin pumps and the adverse impact of macroeconomic challenges. In the past year, this Zacks Rank #3 (Hold) company has surged 56.2% compared with 10.9% growth of the industry and a 24.9% rise of the S&P 500 composite. The renowned medical device company h ...